MAKO Surgical Corp (NASDAQ:MAKO) among the losers and the
stock declined 39.18% to $14.97 on a traded volume of 4.28 million shares. Canaccord
Genuity restated a hold rating on the stock and the price target is set at
$16.0. The Company announced its selected operating results for the quarter
ended June 30, 2012. Nine RIO systems were sold during the second quarter .Out
of nine, eight were sold to domestic customers and one was sold to a
distributor in China. During the second quarter, 2,590 MAKOplasty procedures
were performed, of which 2,494 were performed at domestic sites. MAKO reduced 2012 MAKOplasty annual procedure
guidance to 11,000 to 12,000.
Chelsea Therapeutics International Ltd (NASDAQ:CHTP)
declined 12.82% to $1.08. The Board of Directors intends to promptly implement
a corporate reorganization that includes a reduction in force, executive
changes and changes to the Company's Board of Directors. The Board has authorized
a plan to explore and evaluate strategic options for the Company. All the
strategies wil help in optimizing long-term stockholder value.
Bristol Myers Squibb Co (NYSE:BMY) went down 0.11% to
$34.98. B&R Acquisition, wholly owned subsidiary of Bristol-Myers Squibb
Company will purchase all outstanding shares of common stock of Amylin
Pharmaceuticals Inc. Amylin will receive $31.00 in cash for each share of
Amylin common stock validly tendered and not validly withdrawn in the offer.
Hi-Tech Pharmacal Co (NASDAQ:HITK) slipped 0.30% to
$30.41. The Company reported fourth
quarter profit of $9.9 million or 73 cents per share compared to $12.6 million
or 98 cents in the prior year period. Revenue increased 7.2% to $61.3 million.
However, analysts projected earnings of 78 cents on revenue of $58 million.
Gross margin slipped to 51.9% from 54.7% due to decline in price of Fluticasone
Propionate nasal spray and Dorzolamide ophthalmic products. Research and
development costs rose 45% to $3.4 million and interest expense soared to
$163,000 from $11,000.
Luminex Corporation (NASDAQ:LMNX) plunged 2.85% to
$19.48.The Company has agreed to acquire GenturaDx in a cash deal worth $50
million that will help to expand Luminex's presence in the market. GenturaDx
aims to make nucleic acid testing more affordable and practical for
laboratories. The company is developing a polymerase chain reaction system to
enable rapid and accurate diagnosis with minimal sample volume. Luminex expects
commercial availability of assays for use with the system by early 2014.
No comments:
Post a Comment